Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 08/25/2020

Summary

Jean-Francois Formela, a director of Translate Bio, Inc. [TBIO], reports in this Form 4 sales of common stock by Atlas Venture Fund VIII, L.P. on three dates. Table I lists 34,410 shares sold on 08/25/2020 at a weighted average price of $15.0003, 44,381 shares on 08/26/2020 at $14.7979 and 10,097 shares on 08/27/2020 at $14.3822, leaving 3,833,122 shares owned indirectly. The footnotes give the price ranges, from $14.25 - $14.61 to $15.00 - $15.01, and describe Atlas Venture Associates VIII, L.P. and Atlas Venture Associates VIII, Inc. as general partners. Dr. Formela, a director of AVA VIII INC, disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest. Ommer Chohan signs as attorney in fact on 08/27/2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * FORMELA JEAN FRANCOIS (Last) (First) (Middle) C/O TRANSLATE BIO, INC. 29 HARTWELL AVENUE (Street) LEXINGTON MA 02421 (City) (State) (Zip) | FORMELA JEAN FRANCOIS | (Last) | (First) | (Middle) | C/O TRANSLATE BIO, INC. | 29 HARTWELL AVENUE | LEXINGTON | MA | 02421 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Translate Bio, Inc. [ TBIO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 08/25/2020
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock (1) | 08/25/2020 | S | 34,410 | D | $ 15.0003 (2) | 3,887,600 | I | See Footnote (5)
Common Stock (1) | 08/26/2020 | S | 44,381 | D | $ 14.7979 (3) | 3,843,219 | I | See Footnote (5)
Common Stock (1) | 08/27/2020 | S | 10,097 | D | $ 14.3822 (4) | 3,833,122 | I | See Footnote (5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Represents shares sold by Atlas Venture Fund VIII, L.P. ("Atlas VIII"). Atlas Venture Associates VIII, L.P. ("AVA VIII LP") is the general partner of Atlas VIII. Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 - $15.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 - $14.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.
5. These shares are held directly by Atlas VIII. The sole general partner of Atlas VIII is AVA VIII LP. AVA VIII INC is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
By: /s/ Ommer Chohan -Attorney in Fact | 08/27/2020
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_TBIO_4_filed2020-08-27_0001104659-20-099718.xml

Size

19,205 bytes

SHA-256

b4fcae5d7e1905717f3edd878dce97a870c801838e3bf9627db0058c268ba19c

Our copy

SEC_TBIO_4_filed2020-08-27_0001104659-20-099718.xml

Original

www.sec.gov